PatientsLikeMe is one of 10 biomedicine companies included in Technology Review’s 50 Most Innovative Companies (TR50) for 2012 [1].
Archives for 2012
Romney Flip Flops on the Repeal of Obamacare
September 10, 2012 | by
GOP presidential candidate Mitt Romney, who has unambiguously said that he, if elected president, will repeal the Patient Protection and Affordable Care Act (PPACA), stated yesterday on NBC’s Meet the Press that he would not want to repeal all of the healthcare law [1]. The position is an abrupt turn on an early campaign promise.
Democrats Tout Healthcare Reform on First Night of National Convention
September 6, 2012 | by
On Tuesday this week, Democrats spent much of the opening night of the Democratic National Convention promoting the Patient Protection and Affordable Care Act (PPACA), which became law in March 2010 and was upheld by the U.S. Supreme Court against Republican-led opposition in June 2012.
Have a Question for a Physician? There’s an App for That
September 6, 2012 | by
When people have a medical question, they schedule an appointment to see their doctor. Palo Alto, California-based HealthTap aims to change that. The company’s free web and mobile applications enable 24/7 access to personalized, relevant and trusted health information from thousands of leading doctors without leaving your home or office.
At the HealthTap website, users post questions and doctors post brief answers. The service is free and the doctors aren’t paid. Instead, they are allowed to use the resource to enhance their real-life practice with more efficient patient visits (saving everyone time and money), as well as build their reputation and attract new patients.
NIH Researchers Implicate Unique Cell Type in Multiple Sclerosis
August 29, 2012 | by
Researchers at the National Institutes of Health have found evidence that a unique type of immune cell contributes to multiple sclerosis (MS). Their discovery helps define the effects of one of the newest drugs under investigation for treating MS — daclizumab — and could lead to a new class of drugs for treating MS and other autoimmune disorders.
